John Q. Trojanowski

TL;DR: Concurrent cerebrovascular disease is a common neuropathological finding in aged subjects with dementia, is more common in Alzheimer's disease than in other neurodegenerative disorders, especially in younger subjects, and lowers the threshold for dementia due to Alzheimer’s disease and α-synucleinopathies, which suggests that these disorders should be targeted by treatments for cerebroVascular disease.

TL;DR: Cerebrospinal fluid assays showing low levels of Aβ 42 and high levels of tau come closest to fulfilling criteria for a useful biomarker, and apolipoprotein E e4 allele can add confidence to the clinical diagnosis.

TL;DR: It is speculated that distinct strains of pathological α-synuclein likely exist in neurodegenerative disease brains and may underlie the tremendous heterogeneity of synucleinopathies.

TL;DR: Experimental studies are attempting to determine whether TDP43-mediated neurodegeneration results from a gain or a loss of function of the protein, and the distinct possibility of pleotropic or combined effects.

TL;DR: Levels of isoprostane 8,12-iso-iPF(2alpha)-VI found in cerebrospinal fluid, plasma, and urine of subjects with MCI imply that individuals withMCI have increased brain oxidative damage before the onset of symptomatic dementia.